

Clinical Trials of Parkinson’s Disease Drug Therapies
Change in Completion Date Dashboard: Q1 2023
 posted on ClinicalTrials.gov between Jan. 1, 2023, and Mar. 31, 2023

ClinicalTrials.gov identifier (NCT)	Agent	Company / Sponsor	Agent Description	Phase	Trial Title	Enrollment	Prior Primary Completion Date	New Primary Completion Date	Change (Days)
NCT03683225	CTC-413	Chase Therapeutics	Extended-release pramipexole	Phase 2	A Study to Evaluate CTC-413 in Patients With Parkinsonian Type Disorders	24	1-Dec-2019	30-Dec-2023	1490
NCT05543252	UCB0599	UCB and Neuropore (NPT 200-11)	Inhibitor of aSN misfolding	Phase 2	An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of UCB0599 in Study Participants With Parkinson's Disease	270	28-Dec-2027	10-Dec-2029	713
NCT04377945	JM-010 (Buspirone/Zolmitriptan)	Contera Pharma/Bukwang	Serotonin 1 receptor agonist combination (buspirone and zolmitriptan)	Phase 2	Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components	188	12-Dec-2022	17-Jul-2024	583
NCT04976127	Talineuren	Innomedica	GM1 in liposomes	Phase 1	Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients	22	1-Dec-2022	1-Jun-2024	548
NCT04542499	Tavapadon (PF-06649751)	Cerevel	Dopamine D1/5 partial agonist	Phase 3	Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	368	1-Feb-2023	1-Jun-2024	486
NCT04223193	Tavapadon (PF-06649751)	Cerevel	Dopamine D1/5 partial agonist	Phase 3	Flexible-Dose Trial in Early Parkinson's Disease (PD)	296	1-Jul-2023	1-Oct-2024	458
NCT04760769	Tavapadon (PF-06649751)	Cerevel	Dopamine D1/5 partial agonist	Phase 3	Open-label Trial in Parkinson's Disease (PD)	800	1-Nov-2024	1-Jan-2026	426
NCT02879136	Methylphenidate/Atomoxetine	Cleveland Clinic	Norepinephrine-dopamine reuptake inhibitor/norepinephrine transport inhibitor	Early Phase 1	TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease	42	1-Dec-2023	1-Dec-2024	366
NCT04201093	Tavapadon (PF-06649751)	Cerevel	Dopamine D1/5 partial agonist	Phase 3	Fixed-Dose Trial in Early Parkinson's Disease (PD)	522	1-Sep-2023	1-Sep-2024	366
NCT02616120	SQJZ herbal mixtures	Dongzhimen Hospital, Beijing	Herbal mixture	Phase 2	Effect of SQJZ Herbal Mixtures on Non-motor Symptoms of Parkinson's Disease	240	1-Dec-2022	1-Dec-2023	365

ClinicalTrials.gov identifier (NCT)	Agent	Company / Sponsor	Agent Description	Phase	Trial Title	Enrollment	Prior Primary Completion Date	New Primary Completion Date	Change (Days)
NCT02914366	Ambroxol	Lawson Health Research Institute	Cough medicine, Gcase enhancer	Phase 2	Ambroxol as a Treatment for Parkinson's Disease Dementia	55	1-Dec-2022	1-Dec-2023	365
NCT03575195	Rifaximin	Taipei Medical University	Antibiotic	Phase 1 Phase 2	Microbiota Intervention to Change the Response of Parkinson's Disease	86	1-Dec-2022	1-Dec-2023	365
NCT03149809	Solifenacin	Astellas Pharma	Antimuscarinic bladder relaxant	Phase 3	Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease	90	30-Dec-2022	31-Aug-2023	244
NCT04273932	Lithium	Buffalo University	Protein kinase C inhibitor (treatment for bipolar disorder)	Phase 1	Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	19	1-Dec-2022	15-Jun-2023	196
NCT05603312	AAV-GAD	MeiraGTx	Gene therapy	Phase 1 Phase 2	A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants	14	1-Sep-2023	1-Mar-2024	182
NCT03968133	Ecologic BARRIER 849 (Probiotic)	British Columbia University	Probiotic	Phase 2	Treating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic	61	1-Dec-2022	31-May-2023	181
NCT04006210	ND0612	Mitsubishi Tanabe/Neuroderm	Sub-cutaneous L-DOPA	Phase 3	Efficacy, Safety and Tolerability Study of ND0612 vs. Oral IR-LD/CD in Subjects With PD Experiencing Motor Fluctuations	381	21-Oct-2022	1-Nov-2022	11
NCT04658186	UCB0599	UCB and Neuropore (NPT 200-11)	Inhibitor of aSN misfolding	Phase 2	A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease	450	18-Jul-2024	11-Apr-2024	-98
NCT04651153	UCB7853	UCB and Neuropore	aSN antibody	Phase 1	A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)	57	24-Nov-2023	21-Jul-2023	-126
NCT05634876	UB-312	Vaxxinity (was United Neuroscience)	"Endobody" to aSN	Phase 1 Phase 2	UB-312 in Patients With Synucleinopathies	8	1-Oct-2025	1-Apr-2025	-183